News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Supernus Pharmaceuticals (SUPN) To Attend FBR Healthcare Conference In September



8/20/2014 7:34:14 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will be hosting investor meetings during the FBR Healthcare Conference.

Date: Wednesday, September 3
Place: Four Seasons Hotel, Boston

Investors interested in arranging a meeting during this conference should contact the FBR meeting coordinator.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. 301-838-2591 or Investor Contact: Cockrell Group 877-889-1972 investorrelations@thecockrellgroup.com cockrellgroup.com

Supernus Pharmaceuticals, Inc.

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES